{
    "clinical_study": {
        "@rank": "51760", 
        "arm_group": [
            {
                "arm_group_label": "creatine monohydrate", 
                "arm_group_type": "Experimental", 
                "description": "6g qd for 6 weeks"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "6g qd for 6 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether creatine monohydrate is effective as an\n      adjuvant treatment for bipolar depression."
        }, 
        "brief_title": "Creatine Monohydrate as Adjuvant Therapy for Bipolar Depression", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Bipolar I Disorder", 
            "Current Episode Depressed"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Bipolar Disorder", 
                "Depression", 
                "Depressive Disorder"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Individuals eligible for the study will be adults aged 18 to 60 years of age who met\n             DSM-IV criteria assessed by the SCID (Structural Clinical Interview for DSM-IV) for\n             type I bipolar disorder, current episode depressed.\n\n          -  Patients who have scored > 19 on the Montgomery-Asberg Depression Rating Scale\n             (MADRS) will be included, although more than two weeks of treatment with lithium\n             (serum level> 0.8 mEq / L), valproate (serum levels> 50 mg / L) or quetiapine\n             (300-600mg/dia dose) or drug combination.\n\n          -  Antipsychotics, anticonvulsants, benzodiazepines, and thyroid supplementation will be\n             allowed if the dose has remained stable over the past two weeks.\n\n          -  Antidepressants will be allowed if the dosage has remained stable for 4 weeks.\n\n        Exclusion Criteria:\n\n          -  Subjects with substance abuse within 2 weeks before inclusion or substance dependence\n             up to 2 months will not be included.\n\n          -  Other exclusion criteria will be:\n\n               -  diagnosis of schizophrenia,\n\n               -  dementia,\n\n               -  delirium,\n\n               -  epilepsy,\n\n               -  mental retardation,\n\n               -  clinically unstable medical illnesses,\n\n               -  preexisting renal disease,\n\n               -  history of hypersensibility to creatine.\n\n          -  Not included are individuals at high risk for suicidal or homicidal behavior or\n             self-mutilation will not be included.\n\n          -  Women with gestational potential can only be included if they are using reliable\n             contraception."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655030", 
            "org_study_id": "CR-BD-RCT"
        }, 
        "intervention": [
            {
                "arm_group_label": "creatine monohydrate", 
                "intervention_name": "creatine monohydrate", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 7, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Sao Paulo", 
                    "country": "Brazil", 
                    "state": "SP", 
                    "zip": "01060-970"
                }, 
                "name": "Institute of Psychiatry - HC-FMUSP"
            }
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of Creatine Monohydrate as Adjunctive Therapy for Bipolar Depression", 
        "other_outcome": [
            {
                "measure": "CGI (Clinical Global Impressions Scale) - Severity and Improvement", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "measure": "YMRS (Young Mania Rating Scale)", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }
        ], 
        "overall_contact": {
            "email": "ricardo.toniolo@uol.com.br", 
            "last_name": "Ricardo Toniolo, MD", 
            "phone": "55 11 26617928"
        }, 
        "overall_official": {
            "affiliation": "Bipolar Disorder Research Program, Coordinator, IPq-HC-FMUSP", 
            "last_name": "Beny Lafer, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Committee of Ethics in Research"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "MADRS (Montgomery-Asberg depression Rating Scale)", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655030"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Sao Paulo", 
            "investigator_full_name": "Ricardo Alexandre Toniolo", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "HDRS-17 (Hamilton Depression Rating Scale - 17-item version)", 
            "safety_issue": "No", 
            "time_frame": "6 weeks"
        }, 
        "source": "University of Sao Paulo", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Sao Paulo", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}